How to Prescribe Megestrol Acetate (Megace) Oral Suspension
For adult cancer patients with appetite loss, prescribe Megace ES oral suspension 625 mg (5 mL or one teaspoon) once daily, which is the FDA-approved starting dose for this concentrated formulation. 1
Critical Prescribing Details
Dose and Formulation
- Megace ES (concentrated formula): 625 mg/day = 5 mL (one teaspoon) once daily 1
- Standard Megace suspension: 800 mg/day = 20 mL daily (if using non-ES formulation) 1
- Critical warning: These are NOT interchangeable—Megace ES contains 125 mg/mL while standard formulation contains 40 mg/mL 1
Prescription Instructions
Write the prescription as:
- Medication: Megestrol acetate oral suspension (Megace ES)
- Dose: 625 mg (5 mL)
- Frequency: Once daily
- Instructions: Shake container well before each use 1
- Quantity: 150 mL bottle (30-day supply)
- Refills: 2-3 refills initially, as clinical trials showed efficacy at 400-800 mg daily doses 1
Evidence-Based Rationale
Efficacy Profile
- Megestrol acetate improves appetite (RR 2.57,95% CI 1.48-4.49) and weight gain (RR 1.55,95% CI 1.06-2.26) compared to placebo in cancer cachexia 2
- Higher doses (400-800 mg daily) show greater appetite improvement with positive dose-response effect 2, 1
- Weight gain is primarily adipose tissue rather than skeletal muscle 2
Dose Escalation Strategy
- Start: 625 mg daily (Megace ES) or 800 mg daily (standard formulation) 1
- If inadequate response after 2-4 weeks: Can escalate dose, as studies used up to 1,280 mg/day 3
- Lower doses: 160 mg/day may be reasonable for initial treatment based on cost considerations, though less effective 3
Critical Safety Warnings
Major Adverse Events
- Thromboembolic events: RR 1.84 (95% CI 1.07-3.18)—monitor for DVT/PE 2
- Increased mortality risk: RR 1.42 (95% CI 1.04-1.94) in meta-analysis 2
- Edema: RR 1.36 (95% CI 1.07-1.72) 2
- Adrenal suppression: Documented in clinical use 4
Contraindications
- Pregnancy Category X: Absolutely contraindicated in pregnancy 1
- Require contraception in women of childbearing potential 1
- Discontinue breastfeeding if medication required 1
Drug Interactions
- Indinavir: Decreases indinavir levels by ~36% (Cmax) and ~28% (AUC)—consider higher indinavir dose 1
- No dose adjustment needed for zidovudine or rifabutin 1
Patient Counseling Points
- Inform patients this is a concentrated formula different from standard megestrol acetate suspensions 1
- Expected timeline: Appetite improvement typically seen within 2 weeks 5
- Report immediately: Leg swelling, chest pain, shortness of breath (thromboembolism signs) 2
- Common side effects: Mild edema, weight gain 2, 6